Soleus Capital Management L.P. Acquires 72,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Soleus Capital Management L.P. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 266.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 99,050 shares of the company's stock after buying an additional 72,000 shares during the period. Soleus Capital Management L.P. owned 0.08% of Vaxcyte worth $8,108,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte in the fourth quarter valued at about $28,000. Smartleaf Asset Management LLC increased its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI acquired a new stake in shares of Vaxcyte in the fourth quarter valued at about $41,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares during the period. Finally, Assetmark Inc. increased its stake in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after buying an additional 775 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Vaxcyte stock traded down $1.41 during mid-day trading on Friday, reaching $32.54. The stock had a trading volume of 1,763,863 shares, compared to its average volume of 1,367,883. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The stock's 50-day simple moving average is $38.53 and its 200-day simple moving average is $69.43. The firm has a market capitalization of $4.20 billion, a PE ratio of -7.07 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the business earned ($0.85) earnings per share. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PCVX shares. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Bank of America decreased their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.